MindWalk Research & publications

Phase 3 - ANX005 - Annexon Biosciences

• Target: Complement C1q. Indication: Guillain-Barre Syndrome. Status: Active (GALLOP Phase 3; FDA Breakthrough Therapy designation).
• MindWalk discovered lead antibodies 1C7, 2A1, 3A2, 5A3. ANX005 is wholly owned and developed by Annexon Biosciences; MindWalk's contribution was discovery-stage only.
• Patent: Anti-complement factor C1Q antibodies and uses thereof (US20190211084, 2019) 

Phase 2/3 - ARGX-119 - argenx (NASDAQ: ARGX)

• Target: MuSK (muscle-specific kinase). Indication: Congenital Myasthenic Syndrome. Status: Phase 2/3 planned for 2026; first-in-class MuSK agonist antibody.
• argenx selected and humanized ARGX-119 from a panel of anti-MuSK lead antibodies discovered at MindWalk. ARGX-119 is wholly owned and developed by argenx; MindWalk's contribution was discovery-stage only.
• Peer-reviewed: Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models (iScience, 2024) 

• Also: ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in models of MuSK myasthenia gravis (Science Translational Medicine, 2024) 

Phase 2 - Vudalimab (XmAb20717) - Xencor (NASDAQ: XNCR)

• Target: PD-1 x CTLA-4 bispecific. Indication: Metastatic castration-resistant prostate cancer; solid tumors. Status: Active (Phase 2, multiple solid tumor indications).
• The anti-PD-1 antibody panel was generated by MindWalk and feeds Xencor's bispecific platform. The Xencor clinical programs (vudalimab, XmAb306, XmAb808, and others) are wholly owned by Xencor; MindWalk's contribution was discovery-stage hybridoma generation only.
• Patent: Bispecific and monospecific antibodies using novel anti-PD-1 sequences (US20190263909, 2019)

Phase 2 - CIT-013 - Citryll BV

• Target: Citrullinated histones H2A/H4 (NET formation). Indication: Rheumatoid arthritis; hidradenitis suppurativa; NET-mediated inflammatory diseases. Status: Active - Phase 2a RA (NCT06567470), Phase 2a HS (NCT06993233), Phase 2 PET imaging (NCT07147959), Phase 1 SC dosing (NCT07499908).
• CIT-013 is a therapeutic anti-citrullinated protein antibody (tACPA) that inhibits NET formation; the therapeutic inventors also produced the gold-standard anti-CCP diagnostic at MindWalk. CIT-013 is wholly owned and developed by Citryll BV; MindWalk holds no ownership in the asset.
• Trials: 

Phase 1b - PMN310 - ProMIS Neurosciences

• Target: Abeta oligomers (misfolded). Indication: Alzheimer's Disease. Status: Active - Phase 1b (NCT05948124); data expected 2026.
• Conformation-selective antibodies that bind toxic misfolded protein were discovered under the ImmunoPrecise Antibodies name. PMN310 is wholly owned and developed by ProMIS Neurosciences; MindWalk's contribution was discovery-stage only.
• Trial: 

• Peer-reviewed: Rational generation of monoclonal antibodies selective for pathogenic forms of alpha-synuclein (Biomedicines, 2022)  

Phase 1 - CLN-619 - Cullinan Oncology (NASDAQ: CGEM)

• Target: MICA/MICB (NKG2D ligands). Indication: Solid tumors. Status: Active - Phase 1 (NCT05615493).
• The anti-MICA/MICB antibody panel was discovered and generated by MindWalk. CLN-619 is wholly owned by Cullinan Oncology; MindWalk's contribution was discovery-stage antibody work only.
• Trial:  

• Patent: Antibodies to MICA and MICB proteins (US20190248901, 2019

Phase 1 - XmAb808 - Xencor (NASDAQ: XNCR)

• Target: PD-L1 x CD28 bispecific. Indication: Solid tumors. Status: Active - Phase 1.
• MindWalk discovered the antibody used in Xencor's CD28 co-stimulatory bispecific. XmAb808 is wholly owned by Xencor; MindWalk's contribution was discovery-stage only.
• Patent: Bispecific antibodies that bind PD-L1 and CD28 (US20220135684, 2022)

Phase 1/2 - OR502 - OncoResponse

• Target: LILRB2 (ILT4). Indication: Advanced solid tumors (immuno-oncology). Status: Active - Phase 1/2; Phase 1 data (SITC 2024) reported a 65% disease control rate (2 PR + 9 SD, N=17).
• OR502's parental rabbit monoclonal antibody was generated using ImmunoPrecise Antibodies' B cell Select® platform. OR502 is wholly owned and developed by OncoResponse; MindWalk's contribution was discovery-stage rabbit B cell antibody generation only.
• Trial:

• Reference: OR502, a best-in-class anti-LILRB2 antibody that enhances both innate and adaptive anti-tumor immune responses (SITC 2023, JITC). Note: SITC conference abstract; not a single peer-reviewed PubMed record. 

Preclinical - OR641 - OncoResponse

• Target: LILRB1 x LILRB2 (dual antagonist). Indication: Solid tumors (immuno-oncology). Status: IND-enabling studies; cell line development completed.
• OR641 is a humanized dual antagonist derived from rabbit B cells generated using ImmunoPrecise's B cell Select platform. OR641 is wholly owned by OncoResponse; MindWalk's contribution was discovery-stage only.
• Reference: OR641, a novel dual antagonist antibody targeting LILRB1 and LILRB2 that promotes a Th1-like immune response (SITC 2023, JITC). Note: SITC conference abstract; not a single peer-reviewed PubMed record. 

Phase 1 (Discontinued) - LAVA-1207 - Lava Therapeutics

• Target: Vdelta2-TCR x tumor targets. Indication: Metastatic castration-resistant prostate cancer. Status: Discontinued December 2024 (Lava restructured).
• MindWalk provided VHH and protein-expression support for Lava's gamma-delta T-cell engager platform. LAVA-1207 was wholly owned by Lava Therapeutics; MindWalk's contribution was discovery- and expression-stage support only.
• Peer-reviewed: Vdelta2 T-cell engagers bivalent for Vdelta2-TCR binding provide anti-tumor immunity (iScience, 2024)